RIGEL PHARMACEUTICALS, INC. Operating Lease Cost
RIGEL PHARMACEUTICALS, INC. (RIGL) reported Operating Lease Cost of $200.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-04
- RIGEL PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2026-06-30 was $200.00K, a 50.00% decline year-over-year.
- RIGEL PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2026-03-31 was $200.00K, a 0.00% change year-over-year.
- RIGEL PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2025-12-31 was $160.00K, a 3.03% decline year-over-year.
- RIGEL PHARMACEUTICALS, INC. operating lease, cost for the quarter ending 2025-09-30 was $160.00K, a 3.61% decline year-over-year.
- RIGEL PHARMACEUTICALS, INC. operating lease, cost for fiscal 2025 was $635.00K, a 4.22% decline from fiscal 2024.
- RIGEL PHARMACEUTICALS, INC. operating lease, cost for fiscal 2024 was $663.00K, a 40.22% decline from fiscal 2023.
- RIGEL PHARMACEUTICALS, INC. operating lease, cost for fiscal 2023 was $1.11M, a 79.73% decline from fiscal 2022.
- RIGEL PHARMACEUTICALS, INC. operating lease, cost for fiscal 2022 was $5.47M, a 2.05% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 3 month as first filed | Operating Lease, Cost 6 month | Operating Lease, Cost 6 month as first filed | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $200.00K 10-Q · filed 2026-08-04 | $200.00K 10-Q · filed 2026-08-04 | $560.00K derived: sum of 3 quarters · filed 2026-08-04 | $720.00K derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2026-03-31 | $200.00K 10-Q · filed 2026-05-05 | $360.00K derived: sum of 2 quarters · filed 2026-05-05 | $520.00K derived: sum of 3 quarters · filed 2026-05-05 | $920.00K derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-12-31 | $160.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $320.00K derived: sum of 2 quarters · filed 2026-03-03 | $720.00K derived: sum of 3 quarters · filed 2026-08-04 | $635.00K 10-K · filed 2026-03-03 | ||
| 2025-09-30 | $160.00K 10-Q · filed 2025-11-04 | $560.00K derived: sum of 2 quarters · filed 2026-08-04 | $475.00K 10-Q · filed 2025-11-04 | $925.00K derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-06-30 | $400.00K 10-Q · filed 2026-08-04 | $149.00K 10-Q · filed 2025-08-05 | $400.00K 10-Q · filed 2026-08-04 | $315.00K 10-Q · filed 2025-08-05 | $765.00K derived: sum of 3 quarters · filed 2026-08-04 | $931.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $200.00K 10-Q · filed 2026-05-05 | $166.00K 10-Q · filed 2025-05-06 | $365.00K derived: sum of 2 quarters · filed 2026-05-05 | $531.00K derived: sum of 3 quarters · filed 2026-05-05 | $697.00K derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | $165.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $331.00K derived: sum of 2 quarters · filed 2026-03-03 | $497.00K derived: sum of 3 quarters · filed 2026-03-03 | $663.00K 10-K · filed 2026-03-03 | ||
| 2024-09-30 | $166.00K 10-Q · filed 2025-11-04 | $332.00K derived: sum of 2 quarters · filed 2025-11-04 | $498.00K 10-Q · filed 2025-11-04 | $663.00K derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-06-30 | $166.00K 10-Q · filed 2025-08-05 | $332.00K 10-Q · filed 2025-08-05 | $497.00K derived: sum of 3 quarters · filed 2026-03-03 | $663.00K derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-03-31 | $166.00K 10-Q · filed 2025-05-06 | $331.00K derived: sum of 2 quarters · filed 2026-03-03 | $497.00K derived: sum of 3 quarters · filed 2026-03-03 | $663.00K derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2023-12-31 | $165.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $331.00K derived: sum of 2 quarters · filed 2026-03-03 | $497.00K derived: sum of 3 quarters · filed 2026-03-03 | $1.11M 10-K · filed 2026-03-03 | ||
| 2023-09-30 | $166.00K 10-Q · filed 2024-11-07 | $332.00K derived: sum of 2 quarters · filed 2024-11-07 | $944.00K 10-Q · filed 2024-11-07 | $2.39M derived: sum of 4 quarters · filed 2025-03-04 | ||
| 2023-06-30 | $166.00K 10-Q · filed 2024-08-06 | $778.00K 10-Q · filed 2024-08-06 | $2.23M derived: sum of 3 quarters · filed 2025-03-04 | $3.57M derived: sum of 4 quarters · filed 2025-03-04 | ||
| 2023-03-31 | $612.00K 10-Q · filed 2024-05-07 | $2.06M derived: sum of 2 quarters · filed 2025-03-04 | $3.40M derived: sum of 3 quarters · filed 2025-03-04 | $4.74M derived: sum of 4 quarters · filed 2025-03-04 | ||
| 2022-12-31 | $1.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $2.79M derived: sum of 2 quarters · filed 2025-03-04 | $4.13M derived: sum of 3 quarters · filed 2025-03-04 | $5.47M 10-K · filed 2025-03-04 | ||
| 2022-09-30 | $1.34M 10-Q · filed 2023-11-07 | $2.68M derived: sum of 2 quarters · filed 2023-11-07 | $4.02M 10-Q · filed 2023-11-07 | $5.36M derived: sum of 4 quarters · filed 2024-03-05 | ||
| 2022-06-30 | $1.34M 10-Q · filed 2023-08-01 | $2.68M 10-Q · filed 2023-08-01 | $4.02M derived: sum of 3 quarters · filed 2024-03-05 | $5.36M derived: sum of 4 quarters · filed 2024-03-05 | ||
| 2022-03-31 | $1.34M 10-Q · filed 2023-05-02 | $2.68M derived: sum of 2 quarters · filed 2024-03-05 | $4.02M derived: sum of 3 quarters · filed 2024-03-05 | $5.36M derived: sum of 4 quarters · filed 2024-03-05 | ||
| 2021-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $2.68M derived: sum of 2 quarters · filed 2024-03-05 | $4.02M derived: sum of 3 quarters · filed 2024-03-05 | $5.36M 10-K · filed 2024-03-05 | ||
| 2021-09-30 | $1.34M 10-Q · filed 2022-11-03 | $2.68M derived: sum of 2 quarters · filed 2022-11-03 | $4.02M 10-Q · filed 2022-11-03 | $5.36M derived: sum of 4 quarters · filed 2023-03-07 | ||
| 2021-06-30 | $1.34M 10-Q · filed 2022-08-02 | $2.68M 10-Q · filed 2022-08-02 | $4.02M derived: sum of 3 quarters · filed 2023-03-07 | $5.36M derived: sum of 4 quarters · filed 2023-03-07 | ||
| 2021-03-31 | $1.34M 10-Q · filed 2022-05-03 | $2.68M derived: sum of 2 quarters · filed 2023-03-07 | $4.02M derived: sum of 3 quarters · filed 2023-03-07 | $5.36M derived: sum of 4 quarters · filed 2023-03-07 | ||
| 2020-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $2.68M derived: sum of 2 quarters · filed 2023-03-07 | $4.02M derived: sum of 3 quarters · filed 2023-03-07 | $5.36M 10-K · filed 2023-03-07 | ||
| 2020-09-30 | $1.34M 10-Q · filed 2021-11-02 | $2.68M derived: sum of 2 quarters · filed 2021-11-02 | $4.02M 10-Q · filed 2021-11-02 | $5.36M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-30 | $1.34M 10-Q · filed 2021-08-03 | $2.68M 10-Q · filed 2021-08-03 | $4.02M derived: sum of 3 quarters · filed 2022-03-01 | $5.36M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | $1.34M 10-Q · filed 2021-05-05 | $2.68M derived: sum of 2 quarters · filed 2022-03-01 | $4.02M derived: sum of 3 quarters · filed 2022-03-01 | $5.33M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $2.68M derived: sum of 2 quarters · filed 2022-03-01 | $3.99M derived: sum of 3 quarters · filed 2022-03-01 | $5.25M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $1.34M 10-Q · filed 2019-11-05 | $2.65M derived: sum of 2 quarters · filed 2019-11-05 | $3.91M 10-Q · filed 2019-11-05 | |||
| 2019-06-30 | $1.31M 10-Q · filed 2019-08-06 | $2.57M 10-Q · filed 2019-08-06 | ||||
| 2019-03-31 | $1.26M 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |